Escherichia coli F18 Fim41a antibody and antigen (recombinant protein)

 Download 

Diagnostic anti-Escherichia coli F18 Fim41a antibodies pairs and antigen for animal health (animal Swine/Porcine/Pig infectious disease post-weaning diarrhea) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Go to Swine/Porcine/Pig disease testing products collection >>

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-VT-P285-Tg005-Ag01	Recombinant Escherichia coli F18 Fim41a protein	$3090.00
GMP-VT-P285-Tg005-Ab01	Anti-Escherichia coli F18 Fim41a mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P285-Tg005-Ab02	Anti-Escherichia coli F18 Fim41a mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P285-Tg005-Ab03	Anti-Escherichia coli F18 Fim41a human monoclonal antibody (mAb)	$3090.00
GMP-VT-P285-Tg005-Ab04	Anti-Escherichia coli F18 Fim41a human monoclonal antibody (mAb)	$3090.00

Size： 1mg | 10mg | 100mg

Product Description

Cat No.	GMP-VT-P285-Tg005-Ag01
Product Name	Recombinant Escherichia coli F18 Fim41a protein
Pathogen	Escherichia coli F18
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Escherichia coli F18 Fim41a antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Escherichia coli F18 level test of animal Swine/Porcine/Pig infectious disease with post-weaning diarrhea.
Tag	His
Product description	Recombinant Escherichia coli F18 Fim41a proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P285-Tg005-Ab01,GMP-VT-P285-Tg005-Ab02
Pathogen	Escherichia coli F18
Product Name	Anti-Escherichia coli F18 Fim41a mouse monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Recombinant Escherichia coli F18 Fim41a antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Escherichia coli F18 antibodies in Escherichia coli F18 level test of animal Swine/Porcine/Pig infectious disease with post-weaning diarrhea.
Product description	Anti-Escherichia coli F18 Fim41a mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Escherichia coli F18 antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P285-Tg005-Ab03,GMP-VT-P285-Tg005-Ab04
Pathogen	Escherichia coli F18
Product Name	Anti-Escherichia coli F18 Fim41a human monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Human lgG1
Bioactivity validation	Recombinant Escherichia coli F18 Fim41a antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Escherichia coli F18 antibodies in Escherichia coli F18 level test of animal Swine/Porcine/Pig infectious disease with post-weaning diarrhea.
Product description	Anti-Escherichia coli F18 Fim41a mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Pathogen Information

Escherichia coli (E. coli) is a common, Gram-negative bacterial species found in the gut microbiota of humans and animals. Most strains of E. coli are harmless and play a beneficial role in maintaining gut health. However, certain strains such as E. coli F18 can cause serious infections leading to significant morbidity and mortality in both animals and humans.

E. coli F18 is a virulent strain that is known to cause various diseases, including post-weaning diarrhea (PWD), edema disease, and septicemia in piglets. Similar to other pathogenic E. coli strains, E. coli F18 produces enterotoxins and other virulence factors that facilitate its adhesion and colonization in the host’s gastrointestinal tract.

In pigs, E. coli F18 infection typically occurs after weaning, leading to PWD, which is characterized by diarrhea, dehydration, and weight loss. Edema disease is another manifestation of E. coli F18 infection in pigs, which affects piglets between 1-6 weeks of age. The disease is characterized by sudden onset of neurological symptoms such as ataxia, tremors, and convulsions followed by subcutaneous edema.

In humans, E. coli F18 infections can lead to urinary tract infections (UTIs) and sepsis. E. coli F18 is a common cause of UTIs, a common bacterial infection affecting millions worldwide. UTIs can range from mild self-limiting infections such as cystitis to severe infections such as pyelonephritis, which can result in kidney failure and death if left untreated. Septicemia, also known as blood poisoning, is another severe complication of E. coli F18 infection in humans that can lead to organ failure and death.

To diagnose E. coli F18 infections accurately, various diagnostic methods are available. These methods include culture and isolation of the bacterium from infected tissues, DNA-based methods such as PCR, and immunoassays such as ELISA. These methods detect the presence of specific virulence factors or antigens associated with E. coli F18.

Prevention and control of E. coli F18 infections require a multifaceted approach involving interventions aimed at reducing the risk of exposure, including good hygiene practices, vaccination, and implementation of effective biosecurity measures. In veterinary medicine, strategies such as the use of antibiotics, prebiotics, and probiotics have been proposed to reduce the incidence and severity of E. coli F18 infections in pigs. In human medicine, treatment of E. coli F18 infections typically involves the use of antibiotics in combination with supportive care measures.

In conclusion, Escherichia coli F18 is a pathogenic strain that can cause significant morbidity and mortality in both animals and humans. Understanding the clinical manifestations, diagnostic methods, prevention, and control of E. coli F18 infections is critical in reducing the burden of this disease on human and animal health.

About GDU